Tag: plasma fractionation market outlook

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

#Plasma Fractionation Market Growth Potential: How Will Market Size Shift Through 2030?#_x000D_

The plasma fractionation market size has seen rapid growth in recent years. It is anticipated to expand from $34.14 billion in 2025 to $37.63 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.2%. Historically, this market’s growth can be attributed to several factors, including increased demand for immunoglobulins, a rise in the prevalence of hematological disorders, advancements in plasma fractionation technology, the expansion of hospital and clinical infrastructure, and a greater awareness of plasma-derived therapies._x000D_

_x000D_

The plasma fractionation market is projected to undergo significant expansion in the coming years, reaching $55.85 billion by 2030, with a compound annual growth rate (CAGR) of 10.4%. This anticipated growth is fueled by factors such as the increasing adoption of precision medicine, the integration of artificial intelligence in plasma manufacturing, the expansion of global biopharmaceutical collaborations, rising investments in plasma collection centers, and the development of novel plasma-derived therapies. Prominent trends expected during this forecast period include advanced plasma fractionation techniques, the diversification of biopharmaceutical products, enhanced quality control and regulatory compliance, the growth of contract manufacturing organizations (CMOs/CDMOs), and optimized supply chain management for plasma products._x000D_

_x000D_

#Get A Free Sample Report With In-Depth Market Insights:#_x000D_

https://thebusinessresearchcompany.com/sample_request?id=11432073&type=smp&name=Plasma%20Fractionation%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Plasma Fractionation Market Growth Backed By Core Demand Fundamentals#_x000D_

A rising prevalence of chronic illnesses is anticipated to drive expansion in the plasma fractionation market moving ahead. These long-term conditions, requiring continuous medical management for a year or longer, encompass ailments like heart disease, cancer, and diabetes. Providing plasma products for chronic disease patients helps reduce illness, enhances life quality, and offers cost-effective solutions, consequently boosting the need for plasma fractionation. An example of this trend is seen in March 2025, where GOV.UK, a UK-based non-profit government organization, reported that GP noted a type 2 diabetes prevalence of 7.0% among adults aged 17 and over in England in March 2024, marking a rise from 6.8% in March 2023. Hence, a growing incidence of chronic diseases across all age groups is projected to stimulate the growth of the plasma fractionation market._x000D_

_x000D_

#Plasma Fractionation Market Segment Trends And Revenue Contributors#_x000D_

The plasma fractionation market covered in this report is segmented – _x000D_

_x000D_

1) By Product: Immunoglobulins, Coagulation Factors, Albumin, Protease Inhibitors _x000D_

2) By Application: Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology_x000D_

3) By End User: Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes_x000D_

_x000D_

Subsegments:_x000D_

1) By Immunoglobulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG) _x000D_

2) By Coagulation Factors: Factor VIII, Factor IX, Prothrombin Complex Concentrates (PCC) _x000D_

3) By Albumin: Human Albumin, Bovine Serum Albumin (BSA) _x000D_

4) By Protease Inhibitors: Alpha-1 Antitrypsin (AAT), C1 Esterase Inhibitor (C1-INH) _x000D_

_x000D_

#Plasma Fractionation Market Growth Trends Reshaping The Competitive Landscape#_x000D_

Major companies within the market are implementing novel technologies, including high-tech facility processes that transform donated human plasma into vital medicines and leverage advanced technology to make the procedure more streamlined and secure. For example, in March 2023, CSL Behring, a German-based company, inaugurated a new $470 million plasma fractionation facility employing cutting-edge technology to enhance the efficiency and safety of plasma processing, leading to higher quality and more dependable medicines. By increasing the provision of these critical medicines, the facility contributes to meeting the escalating demand, ensuring more patients can access life-saving treatments. Its advanced automation and self-cleaning systems significantly lower the risk of contamination and improve overall hygienic conditions, thereby enhancing patient safety._x000D_

_x000D_

#Plasma Fractionation Market Competitive Landscape: Which Companies Lead The Industry?#_x000D_

Major companies operating in the plasma fractionation market are Baxter International Inc., Bio Products Laboratory Limited, Biotest AG, CSL Limited, Grifols S. A, ADMA Biologics Inc., Green Cross Corporation, Hualan Bioengineering Inc., Intas Pharmaceuticals Ltd., Japan Blood Products Organization, Kedrion S. P. A., Kamada Ltd., LFB Biomedicaments S. A. S, Octapharma AG, Sanquin Plasma Products B. V., Shanghai Raas Blood Products Co. Ltd., Takeda Pharmaceutical Company, Terumo BCT, China Biologic Products Holdings Inc., China National Biotec Group, Emergent BioSolutions Inc., Bharat Serum Vaccines Limited, Plasma Therapeutics, Prothya Biosolutions B. V., BioPharma Plasma LLC, BioLife Plasma Services LP _x000D_

_x000D_

#View The Full Plasma Fractionation Market Report:#_x000D_

https://thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Plasma Fractionation Market Global Footprint: Which Region Leads The Market?#_x000D_

North America was the largest region in the plasma fractionation market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma fractionation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Reach Out To Our Team:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas: +1 310-496-7795_x000D_

Asia: +44 7882 955267 & +91 8897263534_x000D_

Europe: +44 7882 955267_x000D_

Email us at: marketing@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Plasma Fractionation Market Expansion From $37.62 Billion In 2026 To $55.85 Billion In 2030

The value of the plasma fractionation market has experienced considerable expansion in recent years, increasing from $34.14 billion in 2025 to $37.63 billion in 2026, which reflects a compound annual growth rate (CAGR) of 10.2%. This historical growth has been primarily driven by a heightened demand for immunoglobulins, a growing incidence of hematological disorders, progress in plasma fractionation technology, the development of healthcare facilities such as hospitals and clinics, and greater public awareness of therapies derived from plasma.

The plasma fractionation market is anticipated to experience significant expansion in the coming years, with projections indicating it will reach $55.85 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.4%. This forecasted growth is fueled by factors such as the rising uptake of precision medicine, the incorporation of artificial intelligence into plasma manufacturing processes, the growth of worldwide biopharmaceutical partnerships, increased funding for plasma collection facilities, and the creation of innovative plasma-derived treatments. Key developments shaping this period include the emergence of sophisticated plasma fractionation methods, a broader range of biopharmaceutical offerings, stricter quality assurance and regulatory adherence, the growth of contract manufacturing organizations (CMOs/CDMOs), and improvements in the supply chain for plasma-based products.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7543&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Plasma Fractionation Market Demand Drivers: What Is Fueling Industry Growth?

The rising prevalence of chronic conditions is anticipated to drive expansion in the plasma fractionation market moving forward. Chronic diseases are characterized as health issues lasting a year or more, demanding continuous medical care, with examples including heart disease, cancer, and diabetes. Managing patients with these conditions through access to plasma-derived products reduces illness rates, enhances life quality, and offers cost-effectiveness, consequently boosting the need for plasma fractionation. For example, in March 2025, GOV.UK, a non-profit UK government entity, reported that general practitioners recorded type 2 diabetes prevalence at 7.0% among adults aged 17 and over in England in March 2024, up from 6.8% in March 2023. As a result, a growing number of chronic diseases across all age groups is expected to foster plasma fractionation market growth.

Plasma Fractionation Market Segmentation: How Is The Market Structured Across Key Categories?

The plasma fractionation market covered in this report is segmented –

1) By Product: Immunoglobulins, Coagulation Factors, Albumin, Protease Inhibitors

2) By Application: Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology

3) By End User: Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes

Subsegments:

1) By Immunoglobulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Coagulation Factors: Factor VIII, Factor IX, Prothrombin Complex Concentrates (PCC)

3) By Albumin: Human Albumin, Bovine Serum Albumin (BSA)

4) By Protease Inhibitors: Alpha-1 Antitrypsin (AAT), C1 Esterase Inhibitor (C1-INH)

Plasma Fractionation Market Innovation Trends: Which Developments Are Transforming The Industry?

Major players in this sector are rolling out innovative technologies, such as state-of-the-art facility processes that convert donated human plasma into vital medications, leveraging advanced systems to boost both efficiency and safety. For example, in March 2023, CSL Behring, a firm based in Germany, launched a new plasma fractionation facility valued at $470 million. This plant employs cutting-edge technology to enhance the effectiveness and security of plasma processing, thereby ensuring the production of higher-quality and more dependable medicines. By expanding the availability of these essential treatments, the facility addresses the increasing demand, allowing a greater number of patients to access life-saving therapies. Through the use of sophisticated automation and self-cleaning mechanisms, it minimizes contamination risks and elevates hygienic standards, ultimately strengthening patient safety.

Plasma Fractionation Market Competitive Landscape And Leading Companies

Major companies operating in the plasma fractionation market are Baxter International Inc., Bio Products Laboratory Limited, Biotest AG, CSL Limited, Grifols S. A, ADMA Biologics Inc., Green Cross Corporation, Hualan Bioengineering Inc., Intas Pharmaceuticals Ltd., Japan Blood Products Organization, Kedrion S. P. A., Kamada Ltd., LFB Biomedicaments S. A. S, Octapharma AG, Sanquin Plasma Products B. V., Shanghai Raas Blood Products Co. Ltd., Takeda Pharmaceutical Company, Terumo BCT, China Biologic Products Holdings Inc., China National Biotec Group, Emergent BioSolutions Inc., Bharat Serum Vaccines Limited, Plasma Therapeutics, Prothya Biosolutions B. V., BioPharma Plasma LLC, BioLife Plasma Services LP

Access The Complete Plasma Fractionation Market Report:

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Plasma Fractionation Market Regional Outlook: Where Are The Largest Opportunities Located?

North America was the largest region in the plasma fractionation market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma fractionation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Value Outlook For The Plasma Fractionation Market Through 2030?

The plasma fractionation market has seen substantial expansion in recent years. It is projected to grow from $34.14 billion in 2025 to $37.63 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.2%. This historical growth can be linked to several factors, including an increase in demand for immunoglobulins, a rise in the occurrence of hematological disorders, continuous technological advancements within plasma fractionation, the broadening of hospital and clinical infrastructure, and enhanced public awareness regarding plasma-derived treatments.

The plasma fractionation market is anticipated to experience substantial growth in the upcoming years. It is set to expand to $55.85 billion in 2030, achieving a compound annual growth rate (CAGR) of 10.4%. This projected growth within the forecast period can be attributed to the increasing embrace of precision medicine, the incorporation of artificial intelligence in plasma manufacturing, the broadening of global biopharmaceutical partnerships, heightened investments in plasma collection centers, and the creation of innovative plasma-derived treatments. Prominent trends for the forecast period include advanced plasma fractionation techniques, the diversification of biopharmaceutical products, improved quality control and regulatory adherence, the expansion of contract manufacturing organizations (CMOs/CDMOs), and efforts to optimize the supply chain for plasma products.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7543&type=smp

What Important Drivers Are Powering The Plasma Fractionation Market Growth?

The increasing number of chronic diseases is anticipated to stimulate the expansion of the plasma fractionation market in the coming period. Chronic diseases are defined as conditions that persist for 1 year or longer and demand continuous medical care, with examples including heart disease, cancer, and diabetes. Treating patients with chronic diseases by providing access to plasma products is effective in reducing morbidity, improving their quality of life, and being cost-effective, factors that will subsequently boost the demand for plasma fractionation. For instance, in March 2025, according to GOV.UK, a UK-based non-profit government organization, general practitioners documented type 2 diabetes prevalence in adults as 7.0% for those aged 17 and over in England in March 2024, a rise from 6.8% in March 2023. Consequently, a growing incidence of chronic diseases across all age groups is expected to propel the plasma fractionation market growth.

How Does Segment Analysis Break Down The Plasma Fractionation Market Structure?

The plasma fractionation market covered in this report is segmented –

1) By Product: Immunoglobulins, Coagulation Factors, Albumin, Protease Inhibitors

2) By Application: Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology

3) By End User: Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes

Subsegments:

1) By Immunoglobulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Coagulation Factors: Factor VIII, Factor IX, Prothrombin Complex Concentrates (PCC)

3) By Albumin: Human Albumin, Bovine Serum Albumin (BSA)

4) By Protease Inhibitors: Alpha-1 Antitrypsin (AAT), C1 Esterase Inhibitor (C1-INH)

What Trends Are Driving Changes In The Plasma Fractionation Market?

Leading companies in the market are implementing novel technologies, including high-tech facility processes that transform donated human plasma into essential medicines, utilizing advanced methods to enhance efficiency and safety. For example, in March 2023, CSL Behring, a German-based company, inaugurated a new $470 million plasma fractionation facility. This facility incorporates cutting-edge technology to elevate the efficiency and safety of plasma processing, guaranteeing higher quality and more dependable medicines. By expanding the supply of these vital medicines, the facility assists in meeting increasing demand, ensuring a greater number of patients can access life-saving treatments. Its advanced automation and self-cleaning systems contribute to reducing contamination risks and improving overall hygienic conditions, thereby enhancing patient safety.

Which Firms Are Competing In The Plasma Fractionation Market?

Major companies operating in the plasma fractionation market are Baxter International Inc., Bio Products Laboratory Limited, Biotest AG, CSL Limited, Grifols S. A, ADMA Biologics Inc., Green Cross Corporation, Hualan Bioengineering Inc., Intas Pharmaceuticals Ltd., Japan Blood Products Organization, Kedrion S. P. A., Kamada Ltd., LFB Biomedicaments S. A. S, Octapharma AG, Sanquin Plasma Products B. V., Shanghai Raas Blood Products Co. Ltd., Takeda Pharmaceutical Company, Terumo BCT, China Biologic Products Holdings Inc., China National Biotec Group, Emergent BioSolutions Inc., Bharat Serum Vaccines Limited, Plasma Therapeutics, Prothya Biosolutions B. V., BioPharma Plasma LLC, BioLife Plasma Services LP

Access The Complete Plasma Fractionation Market Report:

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

Which Region Commands The Largest Share Of The Plasma Fractionation Market?

North America was the largest region in the plasma fractionation market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma fractionation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Plasma Fractionation Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=7543&type=smp

Browse Through More Reports Similar to the Global Plasma Fractionation Market 2026, By The Business Research Company

Plasma Fractionation Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

Plasma Powder Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-powder-global-market-report

Blood Plasma Derivatives Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-plasma-derivatives-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Plasma Fractionation Market Grow Between 2026 And 2030?

The plasma fractionation market has experienced significant expansion recently. This market is projected to increase from $34.14 billion in 2025 to $37.63 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 10.2%. Historically, this expansion was driven by factors such as an escalating demand for immunoglobulins, a higher incidence of hematological disorders, continuous technological improvements in plasma fractionation, the enlargement of hospital and clinical facilities, and greater public understanding of plasma-derived treatments.

The plasma fractionation market is projected for substantial expansion in the upcoming years. This market is anticipated to reach $55.85 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.4%. The expansion throughout the forecast period can be attributed to the rising adoption of precision medicine, the incorporation of AI into plasma manufacturing, the broadening of global biopharmaceutical collaborations, increased investments in plasma collection centers, and the development of new plasma-derived therapies. Prominent trends for the forecast period include advanced plasma fractionation techniques, diversification of biopharmaceutical products, enhanced quality control and regulatory compliance, the expansion of contract manufacturing organizations (CMOs/CDMOs), and optimized supply chains for plasma products.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7543&type=smp

Which Factors Are Influencing The Growth Of The Plasma Fractionation Market?

A rising incidence of chronic illnesses is anticipated to drive expansion in the plasma fractionation market in the future. Chronic illnesses are defined as conditions persisting for a year or longer, necessitating continuous medical care, with examples encompassing ailments like heart disease, cancer, and diabetes. Providing plasma products for the treatment of individuals with chronic conditions decreases illness, enhances their quality of life, and offers economic benefits, thereby boosting the demand for plasma fractionation. As an illustration, GOV.UK, a UK-based non-profit government body, reported in March 2025 that the prevalence of type 2 diabetes among adults, specifically those aged 17 and over in England, was recorded by GPs as 7.0% in March 2024, representing an increase from 6.8% in March 2023. Consequently, the growing prevalence of chronic diseases across all age groups is projected to stimulate the growth of the plasma fractionation market.

Which Segment Classifications Are Used In The Plasma Fractionation Market Segment Analysis?

The plasma fractionation market covered in this report is segmented –

1) By Product: Immunoglobulins, Coagulation Factors, Albumin, Protease Inhibitors

2) By Application: Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology

3) By End User: Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes

Subsegments:

1) By Immunoglobulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Coagulation Factors: Factor VIII, Factor IX, Prothrombin Complex Concentrates (PCC)

3) By Albumin: Human Albumin, Bovine Serum Albumin (BSA)

4) By Protease Inhibitors: Alpha-1 Antitrypsin (AAT), C1 Esterase Inhibitor (C1-INH)

What Trends Are Influencing The Evolution Of The Plasma Fractionation Market?

Major companies in the market are implementing new technologies, including high-tech facility processes that transform donated human plasma into crucial medicines, utilizing advanced technology to enhance both efficiency and safety. For instance, in March 2023, CSL Behring, a German-based company, launched a new $470 million plasma fractionation facility. This facility employs cutting-edge technology to improve the efficiency and safety of plasma processing, thereby ensuring higher quality and more reliable medicines. By expanding the supply of these vital medicines, the facility helps to satisfy the rising demand, guaranteeing greater patient access to life-saving treatments. With its advanced automation and self-cleaning systems, it minimizes the risk of contamination and improves overall hygienic conditions, consequently enhancing patient safety.

Which Firms Are Contributing To The Plasma Fractionation Market Ecosystem?

Major companies operating in the plasma fractionation market are Baxter International Inc., Bio Products Laboratory Limited, Biotest AG, CSL Limited, Grifols S. A, ADMA Biologics Inc., Green Cross Corporation, Hualan Bioengineering Inc., Intas Pharmaceuticals Ltd., Japan Blood Products Organization, Kedrion S. P. A., Kamada Ltd., LFB Biomedicaments S. A. S, Octapharma AG, Sanquin Plasma Products B. V., Shanghai Raas Blood Products Co. Ltd., Takeda Pharmaceutical Company, Terumo BCT, China Biologic Products Holdings Inc., China National Biotec Group, Emergent BioSolutions Inc., Bharat Serum Vaccines Limited, Plasma Therapeutics, Prothya Biosolutions B. V., BioPharma Plasma LLC, BioLife Plasma Services LP

Get The Full Plasma Fractionation Market Report:

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

Which Region Leads The Plasma Fractionation Market In Terms Of Market Share?

North America was the largest region in the plasma fractionation market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma fractionation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Plasma Fractionation Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

Browse Through More Reports Similar to the Global Plasma Fractionation Market 2026, By The Business Research Company

Plasma Fractionation Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

Plasma Powder Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-powder-global-market-report

Blood Plasma Derivatives Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-plasma-derivatives-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Plasma Fractionation Market Over The Period 2026–2030?

The plasma fractionation market has seen rapid growth in recent years. It is projected to increase from $34.14 billion in 2025 to $37.63 billion in 2026, at a compound annual growth rate (CAGR) of 10.2%. This historical growth can be attributed to factors such as a rise in demand for immunoglobulins, an increased prevalence of hematological disorders, continuous technological advancements in plasma fractionation, the expansion of hospital and clinical infrastructure, and a heightened awareness about plasma-derived therapies.

The plasma fractionation market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $55.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.4%. Factors contributing to this growth during the forecast period include the increasing adoption of precision medicine, the integration of AI into plasma manufacturing, the expansion of global biopharmaceutical collaborations, rising investments in plasma collection centers, and the development of new plasma-derived therapies. Key trends expected during this period involve advanced plasma fractionation techniques, diversification of biopharmaceutical products, improved quality control and regulatory compliance, the expansion of contract manufacturing organizations (CMOs/CDMOs), and optimization of the supply chain for plasma products.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7543&type=smp

Which Major Factors Are Driving The Expansion Of The Plasma Fractionation Market?

The escalating prevalence of chronic diseases is anticipated to drive the expansion of the plasma fractionation market moving forward. These conditions, defined as lasting 1 year or longer and requiring ongoing medical attention, include examples such as heart disease, cancer, and diabetes. Providing chronic disease patients with access to plasma products helps reduce morbidity, enhance their quality of life, and offers a cost-effective solution, which will subsequently elevate the demand for plasma fractionation. For instance, in March 2025, GOV.UK, a UK-based non-profit government organization, reported that the prevalence of type 2 diabetes among adults aged 17 and over in England, as recorded by GPs, reached 7.0% in March 2024, an increase from 6.8% in March 2023. Thus, a rising number of chronic diseases across all age groups is expected to propel the growth of the plasma fractionation market.

How Is The Plasma Fractionation Market Divided Into Its Major Segments?

The plasma fractionation market covered in this report is segmented –

1) By Product: Immunoglobulins, Coagulation Factors, Albumin, Protease Inhibitors

2) By Application: Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology

3) By End User: Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes

Subsegments:

1) By Immunoglobulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Coagulation Factors: Factor VIII, Factor IX, Prothrombin Complex Concentrates (PCC)

3) By Albumin: Human Albumin, Bovine Serum Albumin (BSA)

4) By Protease Inhibitors: Alpha-1 Antitrypsin (AAT), C1 Esterase Inhibitor (C1-INH)

How Are Trends Transforming The Plasma Fractionation Market Landscape?

Key companies operating within the sector are implementing innovative technologies, including high-tech facility processes that transform donated human plasma into essential medicines, employing advanced methods to make the procedure more efficient and secure. For example, in March 2023, CSL Behring, a company based in Germany, launched a new $470 million plasma fractionation facility. This plant utilizes cutting-edge technology to enhance the efficiency and safety of plasma processing, resulting in higher quality and more reliable medications. By expanding the availability of these vital medicines, the facility contributes to meeting the increasing demand, thereby ensuring greater patient access to life-saving therapies. Its sophisticated automation and self-cleaning systems help to mitigate contamination risks and improve overall sanitary conditions, thus bolstering patient safety.

Who Are The Prominent Organizations Shaping The Plasma Fractionation Market?

Major companies operating in the plasma fractionation market are Baxter International Inc., Bio Products Laboratory Limited, Biotest AG, CSL Limited, Grifols S. A, ADMA Biologics Inc., Green Cross Corporation, Hualan Bioengineering Inc., Intas Pharmaceuticals Ltd., Japan Blood Products Organization, Kedrion S. P. A., Kamada Ltd., LFB Biomedicaments S. A. S, Octapharma AG, Sanquin Plasma Products B. V., Shanghai Raas Blood Products Co. Ltd., Takeda Pharmaceutical Company, Terumo BCT, China Biologic Products Holdings Inc., China National Biotec Group, Emergent BioSolutions Inc., Bharat Serum Vaccines Limited, Plasma Therapeutics, Prothya Biosolutions B. V., BioPharma Plasma LLC, BioLife Plasma Services LP

Read the full plasma fractionation market report here:

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

Which Region Currently Holds The Largest Share Of The Plasma Fractionation Market?

North America was the largest region in the plasma fractionation market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma fractionation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Plasma Fractionation Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7543&type=smp

Browse Through More Reports Similar to the Global Plasma Fractionation Market 2026, By The Business Research Company

Plasma Fractionation Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

Plasma Powder Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-powder-global-market-report

Blood Plasma Derivatives Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-plasma-derivatives-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Plasma Fractionation Market Over The Period 2026–2030?

The plasma fractionation market has seen rapid growth in recent years. It is projected to increase from $34.14 billion in 2025 to $37.63 billion in 2026, at a compound annual growth rate (CAGR) of 10.2%. This historical growth can be attributed to factors such as a rise in demand for immunoglobulins, an increased prevalence of hematological disorders, continuous technological advancements in plasma fractionation, the expansion of hospital and clinical infrastructure, and a heightened awareness about plasma-derived therapies.

The plasma fractionation market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $55.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.4%. Factors contributing to this growth during the forecast period include the increasing adoption of precision medicine, the integration of AI into plasma manufacturing, the expansion of global biopharmaceutical collaborations, rising investments in plasma collection centers, and the development of new plasma-derived therapies. Key trends expected during this period involve advanced plasma fractionation techniques, diversification of biopharmaceutical products, improved quality control and regulatory compliance, the expansion of contract manufacturing organizations (CMOs/CDMOs), and optimization of the supply chain for plasma products.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7543&type=smp

Which Major Factors Are Driving The Expansion Of The Plasma Fractionation Market?

The escalating prevalence of chronic diseases is anticipated to drive the expansion of the plasma fractionation market moving forward. These conditions, defined as lasting 1 year or longer and requiring ongoing medical attention, include examples such as heart disease, cancer, and diabetes. Providing chronic disease patients with access to plasma products helps reduce morbidity, enhance their quality of life, and offers a cost-effective solution, which will subsequently elevate the demand for plasma fractionation. For instance, in March 2025, GOV.UK, a UK-based non-profit government organization, reported that the prevalence of type 2 diabetes among adults aged 17 and over in England, as recorded by GPs, reached 7.0% in March 2024, an increase from 6.8% in March 2023. Thus, a rising number of chronic diseases across all age groups is expected to propel the growth of the plasma fractionation market.

How Is The Plasma Fractionation Market Divided Into Its Major Segments?

The plasma fractionation market covered in this report is segmented –

1) By Product: Immunoglobulins, Coagulation Factors, Albumin, Protease Inhibitors

2) By Application: Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology

3) By End User: Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes

Subsegments:

1) By Immunoglobulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Coagulation Factors: Factor VIII, Factor IX, Prothrombin Complex Concentrates (PCC)

3) By Albumin: Human Albumin, Bovine Serum Albumin (BSA)

4) By Protease Inhibitors: Alpha-1 Antitrypsin (AAT), C1 Esterase Inhibitor (C1-INH)

How Are Trends Transforming The Plasma Fractionation Market Landscape?

Key companies operating within the sector are implementing innovative technologies, including high-tech facility processes that transform donated human plasma into essential medicines, employing advanced methods to make the procedure more efficient and secure. For example, in March 2023, CSL Behring, a company based in Germany, launched a new $470 million plasma fractionation facility. This plant utilizes cutting-edge technology to enhance the efficiency and safety of plasma processing, resulting in higher quality and more reliable medications. By expanding the availability of these vital medicines, the facility contributes to meeting the increasing demand, thereby ensuring greater patient access to life-saving therapies. Its sophisticated automation and self-cleaning systems help to mitigate contamination risks and improve overall sanitary conditions, thus bolstering patient safety.

Who Are The Prominent Organizations Shaping The Plasma Fractionation Market?

Major companies operating in the plasma fractionation market are Baxter International Inc., Bio Products Laboratory Limited, Biotest AG, CSL Limited, Grifols S. A, ADMA Biologics Inc., Green Cross Corporation, Hualan Bioengineering Inc., Intas Pharmaceuticals Ltd., Japan Blood Products Organization, Kedrion S. P. A., Kamada Ltd., LFB Biomedicaments S. A. S, Octapharma AG, Sanquin Plasma Products B. V., Shanghai Raas Blood Products Co. Ltd., Takeda Pharmaceutical Company, Terumo BCT, China Biologic Products Holdings Inc., China National Biotec Group, Emergent BioSolutions Inc., Bharat Serum Vaccines Limited, Plasma Therapeutics, Prothya Biosolutions B. V., BioPharma Plasma LLC, BioLife Plasma Services LP

Read the full plasma fractionation market report here:

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

Which Region Currently Holds The Largest Share Of The Plasma Fractionation Market?

North America was the largest region in the plasma fractionation market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma fractionation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Plasma Fractionation Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7543&type=smp

Browse Through More Reports Similar to the Global Plasma Fractionation Market 2026, By The Business Research Company

Plasma Fractionation Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

Plasma Powder Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-powder-global-market-report

Blood Plasma Derivatives Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-plasma-derivatives-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Plasma Fractionation Market Over The Period 2026–2030?

The plasma fractionation market has seen rapid growth in recent years. It is projected to increase from $34.14 billion in 2025 to $37.63 billion in 2026, at a compound annual growth rate (CAGR) of 10.2%. This historical growth can be attributed to factors such as a rise in demand for immunoglobulins, an increased prevalence of hematological disorders, continuous technological advancements in plasma fractionation, the expansion of hospital and clinical infrastructure, and a heightened awareness about plasma-derived therapies.

The plasma fractionation market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $55.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.4%. Factors contributing to this growth during the forecast period include the increasing adoption of precision medicine, the integration of AI into plasma manufacturing, the expansion of global biopharmaceutical collaborations, rising investments in plasma collection centers, and the development of new plasma-derived therapies. Key trends expected during this period involve advanced plasma fractionation techniques, diversification of biopharmaceutical products, improved quality control and regulatory compliance, the expansion of contract manufacturing organizations (CMOs/CDMOs), and optimization of the supply chain for plasma products.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7543&type=smp

Which Major Factors Are Driving The Expansion Of The Plasma Fractionation Market?

The escalating prevalence of chronic diseases is anticipated to drive the expansion of the plasma fractionation market moving forward. These conditions, defined as lasting 1 year or longer and requiring ongoing medical attention, include examples such as heart disease, cancer, and diabetes. Providing chronic disease patients with access to plasma products helps reduce morbidity, enhance their quality of life, and offers a cost-effective solution, which will subsequently elevate the demand for plasma fractionation. For instance, in March 2025, GOV.UK, a UK-based non-profit government organization, reported that the prevalence of type 2 diabetes among adults aged 17 and over in England, as recorded by GPs, reached 7.0% in March 2024, an increase from 6.8% in March 2023. Thus, a rising number of chronic diseases across all age groups is expected to propel the growth of the plasma fractionation market.

How Is The Plasma Fractionation Market Divided Into Its Major Segments?

The plasma fractionation market covered in this report is segmented –

1) By Product: Immunoglobulins, Coagulation Factors, Albumin, Protease Inhibitors

2) By Application: Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology

3) By End User: Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes

Subsegments:

1) By Immunoglobulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Coagulation Factors: Factor VIII, Factor IX, Prothrombin Complex Concentrates (PCC)

3) By Albumin: Human Albumin, Bovine Serum Albumin (BSA)

4) By Protease Inhibitors: Alpha-1 Antitrypsin (AAT), C1 Esterase Inhibitor (C1-INH)

How Are Trends Transforming The Plasma Fractionation Market Landscape?

Key companies operating within the sector are implementing innovative technologies, including high-tech facility processes that transform donated human plasma into essential medicines, employing advanced methods to make the procedure more efficient and secure. For example, in March 2023, CSL Behring, a company based in Germany, launched a new $470 million plasma fractionation facility. This plant utilizes cutting-edge technology to enhance the efficiency and safety of plasma processing, resulting in higher quality and more reliable medications. By expanding the availability of these vital medicines, the facility contributes to meeting the increasing demand, thereby ensuring greater patient access to life-saving therapies. Its sophisticated automation and self-cleaning systems help to mitigate contamination risks and improve overall sanitary conditions, thus bolstering patient safety.

Who Are The Prominent Organizations Shaping The Plasma Fractionation Market?

Major companies operating in the plasma fractionation market are Baxter International Inc., Bio Products Laboratory Limited, Biotest AG, CSL Limited, Grifols S. A, ADMA Biologics Inc., Green Cross Corporation, Hualan Bioengineering Inc., Intas Pharmaceuticals Ltd., Japan Blood Products Organization, Kedrion S. P. A., Kamada Ltd., LFB Biomedicaments S. A. S, Octapharma AG, Sanquin Plasma Products B. V., Shanghai Raas Blood Products Co. Ltd., Takeda Pharmaceutical Company, Terumo BCT, China Biologic Products Holdings Inc., China National Biotec Group, Emergent BioSolutions Inc., Bharat Serum Vaccines Limited, Plasma Therapeutics, Prothya Biosolutions B. V., BioPharma Plasma LLC, BioLife Plasma Services LP

Read the full plasma fractionation market report here:

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

Which Region Currently Holds The Largest Share Of The Plasma Fractionation Market?

North America was the largest region in the plasma fractionation market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma fractionation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Plasma Fractionation Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7543&type=smp

Browse Through More Reports Similar to the Global Plasma Fractionation Market 2026, By The Business Research Company

Plasma Fractionation Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

Plasma Powder Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-powder-global-market-report

Blood Plasma Derivatives Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-plasma-derivatives-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the plasma fractionation market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Plasma Fractionation Market in 2026, and what figure is it projected to hit by 2030?

The plasma fractionation market has witnessed rapid growth in recent years. Its valuation is anticipated to climb from $34.14 billion in 2025 to $37.63 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.2%. The expansion observed in the past period is attributable to several factors, including an increased demand for immunoglobulins, a higher prevalence of hematological disorders, advancements in plasma fractionation technology, the broadening of hospital and clinical infrastructure, and a surge in awareness concerning plasma-derived therapies.

The plasma fractionation market is projected to experience swift expansion in the coming years, anticipated to reach a value of $55.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.4%. The growth during the projected timeframe stems from factors such as the growing embrace of precision medicine, the incorporation of AI into plasma manufacturing processes, the broadening of worldwide biopharmaceutical partnerships, increased funding for plasma collection centers, and the creation of innovative plasma-derived treatments. Key trends anticipated for this forecast period encompass advanced methodologies in plasma fractionation, diversification of biopharmaceutical products, improved quality control measures alongside regulatory adherence, the enlargement of contract manufacturing organizations (CMOs/CDMOs), and efforts to optimize the supply chain for plasma products.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7543&type=smp

Which Drivers Are Affecting Market Participation In The Plasma Fractionation Market?

The increasing prevalence of chronic diseases is anticipated to drive the future expansion of the plasma fractionation market. Chronic conditions are defined as ailments lasting one year or more, requiring ongoing medical attention, and include examples such as heart disease, cancer, and diabetes. Treating patients with chronic diseases using plasma products helps reduce morbidity, improves their quality of life, and is cost-effective, which will, in turn, escalate the demand for plasma fractionation. For instance, in March 2025, GOV.UK, a UK-based non-profit government organization, reported that the prevalence of type 2 diabetes among adults aged 17 and over in England was 7.0% in March 2024, showing an increase from 6.8% in March 2023. Therefore, a growing number of chronic diseases across all age groups is expected to propel the plasma fractionation market growth.

What Segment Categories Are Covered In The Plasma Fractionation Market?

The plasma fractionation market covered in this report is segmented –

1) By Product: Immunoglobulins, Coagulation Factors, Albumin, Protease Inhibitors

2) By Application: Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology

3) By End User: Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes

Subsegments:

1) By Immunoglobulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Coagulation Factors: Factor VIII, Factor IX, Prothrombin Complex Concentrates (PCC)

3) By Albumin: Human Albumin, Bovine Serum Albumin (BSA)

4) By Protease Inhibitors: Alpha-1 Antitrypsin (AAT), C1 Esterase Inhibitor (C1-INH)

Which Trends Are Guiding The Evolution Of The Plasma Fractionation Market?

Leading companies in the market are integrating novel technologies, such as high-tech facility operations that transform donated human plasma into crucial medicines, utilizing advanced methods to enhance both efficiency and safety. For instance, in March 2023, CSL Behring, a German-based firm, unveiled a new $470 million plasma fractionation facility. This facility employs cutting-edge technology to improve the efficacy and safety of plasma processing, thereby ensuring higher quality and more dependable medications. By boosting the supply of these vital medicines, the plant aids in satisfying the increasing demand, guaranteeing more patients receive life-saving treatments. Its sophisticated automation and self-cleaning systems significantly lower the risk of contamination and elevate overall hygienic standards, thereby improving patient safety.

Which Leading Companies Dominate The Plasma Fractionation Market Share?

Major companies operating in the plasma fractionation market are Baxter International Inc., Bio Products Laboratory Limited, Biotest AG, CSL Limited, Grifols S. A, ADMA Biologics Inc., Green Cross Corporation, Hualan Bioengineering Inc., Intas Pharmaceuticals Ltd., Japan Blood Products Organization, Kedrion S. P. A., Kamada Ltd., LFB Biomedicaments S. A. S, Octapharma AG, Sanquin Plasma Products B. V., Shanghai Raas Blood Products Co. Ltd., Takeda Pharmaceutical Company, Terumo BCT, China Biologic Products Holdings Inc., China National Biotec Group, Emergent BioSolutions Inc., Bharat Serum Vaccines Limited, Plasma Therapeutics, Prothya Biosolutions B. V., BioPharma Plasma LLC, BioLife Plasma Services LP

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

How Does The Plasma Fractionation Market Perform Across Major Global Regions?

North America was the largest region in the plasma fractionation market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma fractionation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Plasma Fractionation Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7543&type=smp

Browse Through More Reports Similar to the Global Plasma Fractionation Market 2026, By The Business Research Company

Plasma Fractionation Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

Plasma Powder Market Report 2026

https://www.thebusinessresearchcompany.com/report/plasma-powder-global-market-report

Blood Plasma Derivatives Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-plasma-derivatives-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the plasma fractionation market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The Plasma Fractionation Market Now And By 2029?

The plasma fractionation market has observed substantial growth over recent years. Its size is projected to expand from $31.42 billion in 2024 to $34.14 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.6%. This historical growth can be linked to the increasing prevalence of hemophilia and immunodeficiency disorders, a growing aging population, the escalating demand for immunoglobulins, the expansion of plasma collection centers, and a rising number of surgical procedures.

The plasma fractionation market size is projected to experience substantial expansion over the upcoming years, reaching $50.54 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.3%. This anticipated growth during the forecast period is driven by factors such as increasing worldwide healthcare spending, expanding uses of medicinal products derived from plasma, greater investment in research and development, the need for plasma in managing neurological conditions, and the growth of plasma fractionation facilities. Key trends foreseen in this period involve the creation of novel fractionation technologies, a move towards treatments utilizing albumin and immunoglobulin, increasing demand for specialized plasma products, an emphasis on technologies for inactivating pathogens, and strategic alliances and partnerships within the plasma sector.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7543&type=smp

Which Long-Term Drivers Are Expected To Sustain The Plasma Fractionation Market?

A growing incidence of chronic conditions is anticipated to drive the expansion of the plasma fractionation market in the future. These are ailments lasting a minimum of one year and demanding continuous medical care, encompassing examples like heart disease, cancer, and diabetes. Providing chronic disease patients with plasma products leads to reduced illness, enhanced life quality, and cost efficiency, consequently boosting the demand for plasma fractionation. As an illustration, a January 2023 report from the National Library of Medicine, a US-based organization, indicated that the population aged 50 and above suffering from one or more chronic conditions is forecast to increase by 99.5%, climbing from 71.522 million in 2020 to 142.66 million by 2050 in the United States. Consequently, the rising occurrence of chronic diseases is fueling the expansion of the healthcare analytical testing service market. Thus, a growing prevalence of chronic diseases across all age groups is poised to further stimulate the plasma fractionation market growth.

How Is The Plasma Fractionation Market Classified By Different Segments?

The plasma fractionation market covered in this report is segmented –

1) By Product: Immunoglobulins, Coagulation Factors, Albumin, Protease Inhibitors

2) By Application: Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology

3) By End User: Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes

Subsegments:

1) By Immunoglobulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

2) By Coagulation Factors: Factor VIII, Factor IX, Prothrombin Complex Concentrates (PCC)

3) By Albumin: Human Albumin, Bovine Serum Albumin (BSA)

4) By Protease Inhibitors: Alpha-1 Antitrypsin (AAT), C1 Esterase Inhibitor (C1-INH)

What Current And Upcoming Trends Are Shaping The Plasma Fractionation Market?

Key companies in the market are implementing new technologies, such as advanced facility processes that transform donated human plasma into essential medicines, employing sophisticated methods to enhance efficiency and safety. For example, in March 2023, CSL Behring, a German-based company, launched a new $470 million plasma fractionation facility. This facility utilizes cutting-edge technology to improve the efficiency and safety of plasma processing, thereby ensuring higher quality and more reliable medicines. By boosting the supply of these critical treatments, the facility helps address the rising demand, guaranteeing more patients receive access to life-saving therapies. Its advanced automation and self-cleaning systems also reduce the risk of contamination and improve overall hygienic standards, significantly enhancing patient safety.

Who Are The Primary Market Leaders In The Plasma Fractionation Market?

Major companies operating in the plasma fractionation market include Baxter International Inc., Bio Products Laboratory Limited, Biotest AG, CSL Limited, Grifols S. A, ADMA Biologics Inc., Green Cross Corporation, Hualan Bioengineering Inc., Intas Pharmaceuticals Ltd., Japan Blood Products Organization, Kedrion S. P. A., Kamada Ltd., LFB Biomedicaments S. A. S, Octapharma AG, Sanquin Plasma Products B. V., Shanghai Raas Blood Products Co. Ltd., Takeda Pharmaceutical Company, Terumo BCT, China Biologic Products Holdings Inc., China National Biotec Group, Emergent BioSolutions Inc., Bharat Serum Vaccines Limited, Plasma Therapeutics, Prothya Biosolutions B. V., BioPharma Plasma LLC, BioLife Plasma Services LP

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

Which Regional Markets Are Emerging As Key Centers For The Plasma Fractionation Market?

North America was the largest region in the plasma fractionation market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma fractionation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=7543&type=smp

Browse Through More Reports Similar to the Global Plasma Fractionation Market 2025, By The Business Research Company

Blood And Blood Components Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report

Convalescent Plasma Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report

Patient Blood Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model